{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T12:11:21Z","timestamp":1788610281604,"version":"build-2803163510"},"reference-count":208,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017577","name":"Basic Public Welfare Research Program of Zhejiang Province","doi-asserted-by":"publisher","award":["LQN25H160047"],"award-info":[{"award-number":["LQN25H160047"]}],"id":[{"id":"10.13039\/501100017577","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017577","name":"Basic Public Welfare Research Program of Zhejiang Province","doi-asserted-by":"publisher","award":["LTGY24H160007"],"award-info":[{"award-number":["LTGY24H160007"]}],"id":[{"id":"10.13039\/501100017577","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019976","name":"Science and Technology Bureau of Jiaxing City","doi-asserted-by":"publisher","award":["2024AY10009"],"award-info":[{"award-number":["2024AY10009"]}],"id":[{"id":"10.13039\/501100019976","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872220"],"award-info":[{"award-number":["81872220"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.nano.2026.103006","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:25:35Z","timestamp":1787181935000},"page":"103006","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Engineering design of oxaliplatin nanodelivery systems: Overcoming biological barriers toward precision therapy of colorectal cancer"],"prefix":"10.1016","volume":"76","author":[{"given":"Baojuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhe","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youfa","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoyue","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41572-023-00432-7","article-title":"Young-onset colorectal cancer","volume":"9","author":"Spaander","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.nano.2026.103006_bb0010","article-title":"Trends in colorectal cancer mortality in Europe: retrospective analysis of the WHO mortality database","volume":"351","author":"Ait Ouakrim","year":"2015","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.nano.2026.103006_bb0015","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/gutjnl-2015-310912","article-title":"Global patterns and trends in colorectal cancer incidence and mortality","volume":"66","author":"Arnold","year":"2017","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.nano.2026.103006_bb0020","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw322","article-title":"Colorectal cancer incidence patterns in the United States, 1974\u20132013","volume":"109","author":"Siegel","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.nano.2026.103006_bb0025","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12885-016-2428-5","article-title":"Transanal total mesorectal excision (taTME) for rectal cancer: a systematic review and meta-analysis of oncological and perioperative outcomes compared with laparoscopic total mesorectal excision","volume":"16","author":"Ma","year":"2016","journal-title":"BMC Cancer"},{"issue":"31","key":"10.1016\/j.nano.2026.103006_bb0030","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.2016.67.6049","article-title":"Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6)","volume":"34","author":"Lefevre","year":"2016","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.nano.2026.103006_bb0035","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1200\/JCO.2011.36.4539","article-title":"Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses","volume":"29","author":"Yothers","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.nano.2026.103006_bb0040","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1200\/JCO.2009.23.3452","article-title":"Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial","volume":"28","author":"Roth","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nano.2026.103006_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.728018","article-title":"From immunogenic cell death to immunogenic modulation: select chemotherapy regimens induce a spectrum of immune-enhancing activities in the tumor microenvironment","volume":"11","author":"Fabian","year":"2021","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.nano.2026.103006_bb0050","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nano.2026.103006_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117894","article-title":"Advancements in platinum-based anticancer drug development: a comprehensive review of strategies, discoveries, and future perspectives","volume":"112","author":"Sahoo","year":"2024","journal-title":"Bioorg Med Chem"},{"issue":"5","key":"10.1016\/j.nano.2026.103006_bb0060","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","article-title":"The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs","volume":"116","author":"Johnstone","year":"2016","journal-title":"Chem Rev"},{"issue":"8","key":"10.1016\/j.nano.2026.103006_bb0065","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1039\/C3SC53426J","article-title":"NanoSIMS combined with fluorescence microscopy as a tool for subcellular imaging of isotopically labeled platinum-based anticancer drugs","volume":"5","author":"Legin","year":"2014","journal-title":"Chem Sci"},{"issue":"2","key":"10.1016\/j.nano.2026.103006_bb0070","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1248\/bpb.b13-00540","article-title":"Selective delivery of oxaliplatin to tumor tissue by nanocarrier system enhances overall therapeutic efficacy of the encapsulated oxaliplatin","volume":"37","author":"Lila","year":"2014","journal-title":"Biol Pharm Bull"},{"issue":"29","key":"10.1016\/j.nano.2026.103006_bb0075","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aee6534","article-title":"Multistage microrobots with pH-responsive release of platelet membrane-coated nanoparticles","volume":"12","author":"Sun","year":"2026","journal-title":"Sci Adv"},{"issue":"4","key":"10.1016\/j.nano.2026.103006_bb0080","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1021\/acs.jmedchem.5c03584","article-title":"Flexible-structured cyanine-cyanine conjugate affords highly efficient photothermal therapy via enhanced tumor accumulation and heating performance","volume":"69","author":"Hou","year":"2026","journal-title":"J Med Chem"},{"issue":"1\u20132","key":"10.1016\/j.nano.2026.103006_bb0085","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review","volume":"65","author":"Maeda","year":"2000","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2026.103006_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114614","article-title":"The tumor EPR effect for cancer drug delivery: current status, limitations, and alternatives","volume":"191","author":"Sun","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"10.1016\/j.nano.2026.103006_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/jpm13030389","article-title":"Approaches to improve EPR-based drug delivery for cancer therapy and diagnosis","volume":"13","author":"Subhan","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.nano.2026.103006_bb0100","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jconrel.2022.03.043","article-title":"Strategies to improve the EPR effect: a mechanistic perspective and clinical translation","volume":"345","author":"Ikeda-Imafuku","year":"2022","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.nano.2026.103006_bb0105","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1021\/acs.chemrev.0c00779","article-title":"The use of alternative strategies for enhanced nanoparticle delivery to solid tumors","volume":"121","author":"Izci","year":"2021","journal-title":"Chem Rev"},{"key":"10.1016\/j.nano.2026.103006_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2025.115094","article-title":"Nanomedicine strategies for disulfidptosis activation in SLC7A11-high tumors","volume":"257","author":"Ye","year":"2026","journal-title":"Colloids Surf B: Biointerfaces"},{"issue":"25","key":"10.1016\/j.nano.2026.103006_bb0115","doi-asserted-by":"crossref","first-page":"7906","DOI":"10.1039\/D6TB00469E","article-title":"Ethanol-responsive fluorene-based fluorescent nanoprobes for photodynamic cancer therapy","volume":"14","author":"Mekkeparambath","year":"2026","journal-title":"J Mater Chem B"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb0120","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2025.2527752","article-title":"Nanomedicine initiates ferroptosis for enhanced lung cancer therapy","volume":"32","author":"Xu","year":"2025","journal-title":"Drug Deliv"},{"issue":"2","key":"10.1016\/j.nano.2026.103006_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020376","article-title":"The tumor microenvironment in tumorigenesis and therapy resistance revisited","volume":"15","author":"Dzobo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.nano.2026.103006_bb0130","article-title":"The drug-resistance mechanisms of five platinum-based antitumor agents","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.nano.2026.103006_bb0135","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1039\/C7MT00334J","article-title":"Relevance of copper transporter 1 and organic cation transporters 1\u20133 for oxaliplatin uptake and drug resistance in colorectal cancer cells","volume":"10","author":"Bu\u00df","year":"2018","journal-title":"Metallomics"},{"issue":"17","key":"10.1016\/j.nano.2026.103006_bb0140","doi-asserted-by":"crossref","first-page":"8847","DOI":"10.1158\/0008-5472.CAN-06-0769","article-title":"Organic cation transporters are determinants of oxaliplatin cytotoxicity","volume":"66","author":"Zhang","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.nano.2026.103006_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00085","article-title":"Role of transporters in the distribution of platinum-based drugs","volume":"6","author":"Harrach","year":"2015","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.nano.2026.103006_bb0150","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/sj.bjc.6603866","article-title":"Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil","volume":"97","author":"Chen","year":"2007","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb0155","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2004.09.007","article-title":"Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs","volume":"53","author":"Safaei","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"issue":"15","key":"10.1016\/j.nano.2026.103006_bb0160","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.nano.2026.103006_bb0165","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1016\/j.apsb.2024.10.015","article-title":"Recent advances in reactive oxygen species (ROS)-responsive drug delivery systems for photodynamic therapy of cancer","volume":"14","author":"Hu","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"15","key":"10.1016\/j.nano.2026.103006_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25158423","article-title":"Glutathione-dependent pathways in cancer cells","volume":"25","author":"Kalinina","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.nano.2026.103006_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/biom10101429","article-title":"Role of glutathione in cancer: from mechanisms to therapies","volume":"10","author":"Kennedy","year":"2020","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.nano.2026.103006_bb0180","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1083\/jcb.201804161","article-title":"Glutathione metabolism in cancer progression and treatment resistance","volume":"217","author":"Bansal","year":"2018","journal-title":"J Cell Biol"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb0185","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s42004-022-00661-z","article-title":"A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance","volume":"5","author":"Fronik","year":"2022","journal-title":"Commun Chem"},{"key":"10.1016\/j.nano.2026.103006_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01256","article-title":"The therapeutic potential of DNA damage repair pathways and genomic stability in lung cancer","volume":"10","author":"Burgess","year":"2020","journal-title":"Front Oncol"},{"issue":"13","key":"10.1016\/j.nano.2026.103006_bb0195","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1073\/pnas.1914911117","article-title":"Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents","volume":"117","author":"Thiabaud","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.nano.2026.103006_bb0200","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4103\/0366-6999.176993","article-title":"Excision repair cross-complementation group 1 is a prognostic biomarker in patients with colorectal cancer receiving chemotherapy","volume":"129","author":"Li","year":"2016","journal-title":"Chin Med J"},{"issue":"5","key":"10.1016\/j.nano.2026.103006_bb0205","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.nano.2026.103006_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/cimb47030172","article-title":"Multi-pathway study for oxaliplatin resistance reduction","volume":"47","author":"Ye","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.nano.2026.103006_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101846","article-title":"Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer","volume":"40","author":"Hashemi","year":"2024","journal-title":"Transl Oncol"},{"issue":"12","key":"10.1016\/j.nano.2026.103006_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/cells9122598","article-title":"Hypoxia dictates metabolic rewiring of tumors: implications for chemoresistance","volume":"9","author":"Belisario","year":"2020","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.nano.2026.103006_bb0225","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2174\/138955709788922610","article-title":"HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms","volume":"9","author":"Mar\u00edn-Hern\u00e1ndez","year":"2009","journal-title":"Mini-Rev Med Chem"},{"key":"10.1016\/j.nano.2026.103006_bb0230","article-title":"Extracellular matrix in the tumor microenvironment and its impact on cancer therapy","volume":"6","author":"Henke","year":"2019","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.nano.2026.103006_bb0235","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1186\/s12964-024-01857-7","article-title":"Chemoresistance and the tumor microenvironment: the critical role of cell\u2013cell communication","volume":"22","author":"Wilczy\u0144ski","year":"2024","journal-title":"Cell Commun Signal"},{"issue":"3","key":"10.1016\/j.nano.2026.103006_bb0240","doi-asserted-by":"crossref","first-page":"577","DOI":"10.20517\/cdr.2022.38","article-title":"Exosome secretion from hypoxic cancer cells reshapes the tumor microenvironment and mediates drug resistance","volume":"5","author":"To","year":"2022","journal-title":"Cancer Drug Resist"},{"issue":"4","key":"10.1016\/j.nano.2026.103006_bb0245","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2024.5684","article-title":"Drug resistance and tumor immune microenvironment: an overview of current understandings (review)","volume":"65","author":"Liu","year":"2024","journal-title":"Int J Oncol"},{"key":"10.1016\/j.nano.2026.103006_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.758143","article-title":"Advanced nano-carriers for anti-tumor drug loading","volume":"11","author":"Xiang","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.nano.2026.103006_bb0255","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1021\/acs.molpharmaceut.9b01189","article-title":"Tumor microenvironment stimuli-responsive nanoparticles for programmed anticancer drug delivery","volume":"17","author":"Jia","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nano.2026.103006_bb0260","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2015.06.026","article-title":"Mathematical models of the steps involved in the systemic delivery of a chemotherapeutic to a solid tumor: from circulation to survival","volume":"212","author":"Ulmschneider","year":"2015","journal-title":"J Control Release"},{"issue":"11","key":"10.1016\/j.nano.2026.103006_bb0265","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.tips.2014.09.008","article-title":"Prodrug-based nanoparticulate drug delivery strategies for cancer therapy","volume":"35","author":"Luo","year":"2014","journal-title":"Trends Pharmacol Sci"},{"issue":"12","key":"10.1016\/j.nano.2026.103006_bb0270","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat Nanotechnol"},{"issue":"3","key":"10.1016\/j.nano.2026.103006_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26030602","article-title":"Poly(ethylene glycol)-b-poly(d,l-lactide) nanoparticles as potential carriers for anticancer drug oxaliplatin","volume":"26","author":"Kadina","year":"2021","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.nano.2026.103006_bb0280","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1080\/17425247.2025.2570847","article-title":"Biomimetic nanocarriers for targeted therapy of colorectal cancer","volume":"22","author":"Pathak","year":"2025","journal-title":"Expert Opin Drug Deliv"},{"issue":"11","key":"10.1016\/j.nano.2026.103006_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16111383","article-title":"Drug release via ultrasound-activated nanocarriers for cancer treatment: a review","volume":"16","author":"Al Refaai","year":"2024","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.nano.2026.103006_bb0290","article-title":"Bacteria as nanoparticles carrier for enhancing penetration in a tumoral matrix model","volume":"7","author":"Moreno","year":"2020","journal-title":"Adv Mater Interfaces"},{"issue":"7","key":"10.1016\/j.nano.2026.103006_bb0295","doi-asserted-by":"crossref","DOI":"10.3390\/nano13071140","article-title":"Passing of nanocarriers across the histohematic barriers: current approaches for tumor theranostics","volume":"13","author":"Gareev","year":"2023","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.nano.2026.103006_bb0300","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejpb.2021.05.007","article-title":"Emerging strategies against tumor-associated fibroblast for improved the penetration of nanoparticle into desmoplastic tumor","volume":"165","author":"Yunna","year":"2021","journal-title":"Eur J Pharm Biopharm"},{"issue":"14","key":"10.1016\/j.nano.2026.103006_bb0305","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202110614","article-title":"Bioinspired lipoproteins of furoxans-oxaliplatin remodel physical barriers in tumor to potentiate T-cell infiltration","volume":"34","author":"Wang","year":"2022","journal-title":"Adv Mater"},{"issue":"3","key":"10.1016\/j.nano.2026.103006_bb0310","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1021\/acsabm.1c01234","article-title":"Lipid-coated CaCO3 nanoparticles as a versatile pH-responsive drug delivery platform to enable combined chemotherapy of breast cancer","volume":"5","author":"Xu","year":"2022","journal-title":"ACS Appl Bio Mater"},{"key":"10.1016\/j.nano.2026.103006_bb0315","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.addr.2018.07.007","article-title":"Tumor targeting via EPR: strategies to enhance patient responses","volume":"130","author":"Golombek","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"10.1016\/j.nano.2026.103006_bb0320","first-page":"1621","article-title":"PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma","volume":"25","author":"Yang","year":"2011","journal-title":"Oncol Rep"},{"issue":"2","key":"10.1016\/j.nano.2026.103006_bb0325","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ejpb.2012.02.007","article-title":"Application of different methods to formulate PEG-liposomes of oxaliplatin: evaluation in vitro and in vivo","volume":"81","author":"Zalba","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.nano.2026.103006_bb0330","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2147\/IJN.S502076","article-title":"Enhanced antitumor efficacy and reduced toxicity in colorectal cancer using a novel multifunctional Rg3-targeting nanosystem encapsulated with oxaliplatin and calcium peroxide","volume":"20","author":"Xie","year":"2025","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2026.103006_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120722","article-title":"Effect of paclitaxel\/etoposide co-loaded polymeric nanoparticles on tumor size and survival rate in a rat model of glioblastoma","volume":"604","author":"Maleki","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2026.103006_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2025.107050","article-title":"Navigating tumor microenvironment with TME-responsive nanocarriers: strategies for targeted drug delivery in solid tumor","volume":"110","author":"Rajankar","year":"2025","journal-title":"J Drug Delivery Sci Technol"},{"key":"10.1016\/j.nano.2026.103006_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2025.107701","article-title":"Preparation of polylysine nanoparticles for oxaliplatin delivery and anti-colorectal cancer efficacy study","volume":"115","author":"Xie","year":"2026","journal-title":"J Drug Delivery Sci Technol"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb0350","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat Commun"},{"issue":"19","key":"10.1016\/j.nano.2026.103006_bb0355","doi-asserted-by":"crossref","DOI":"10.3390\/polym14194131","article-title":"Assessment of oxaliplatin-loaded iodine nanoparticles for chemoradiotherapy of human colorectal cancer (HT-29) cells","volume":"14","author":"Rasouli","year":"2022","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.nano.2026.103006_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.matdes.2025.115016","article-title":"Engineering a nano delivery system targets EphA2 for treating colorectal cancer oxaliplatin resistant","volume":"260","author":"Li","year":"2025","journal-title":"Mater Des"},{"issue":"2","key":"10.1016\/j.nano.2026.103006_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020621","article-title":"Cell-membrane-coated nanoparticles for targeted drug delivery to the brain for the treatment of neurological diseases","volume":"15","author":"Li","year":"2023","journal-title":"Pharmaceutics"},{"issue":"30","key":"10.1016\/j.nano.2026.103006_bb0370","article-title":"Neutrophil-mimicking nanomedicine eliminates tumor intracellular bacteria and enhances chemotherapy on liver metastasis of colorectal cancer","volume":"12","author":"Niu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.nano.2026.103006_bb0375","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jconrel.2022.11.044","article-title":"Bioinspired nanovehicle of furoxans-oxaliplatin improves tumoral distribution for chemo-radiotherapy","volume":"353","author":"Qian","year":"2023","journal-title":"J Control Release"},{"issue":"6","key":"10.1016\/j.nano.2026.103006_bb0380","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/1061186X.2024.2349124","article-title":"pH-responsive self-assembled nanoparticles for tumor-targeted drug delivery","volume":"32","author":"Sun","year":"2024","journal-title":"J Drug Target"},{"issue":"9","key":"10.1016\/j.nano.2026.103006_bb0385","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/smll.201303329","article-title":"Near infrared light-triggered drug generation and release from gold nanoparticle carriers for photodynamic therapy","volume":"10","author":"Cheng","year":"2014","journal-title":"Small"},{"key":"10.1016\/j.nano.2026.103006_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112317","article-title":"PH-responsive and folate-coated liposomes encapsulating irinotecan as an alternative to improve efficacy of colorectal cancer treatment","volume":"144","author":"Nunes","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.nano.2026.103006_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120190","article-title":"Oxaliplatin-\/NLG919 prodrugs-constructed liposomes for effective chemo-immunotherapy of colorectal cancer","volume":"255","author":"Shen","year":"2020","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb0400","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1007\/s12672-025-03164-0","article-title":"Folate-modified liposomes for co-delivery of schisandrin A and oxaliplatin to enhance colorectal cancer cell death","volume":"16","author":"Zhou","year":"2025","journal-title":"Discov Oncol"},{"issue":"4","key":"10.1016\/j.nano.2026.103006_bb0405","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1039\/C5CP05778G","article-title":"The thermodynamics of endosomal escape and DNA release from lipoplexes","volume":"18","author":"Avital","year":"2016","journal-title":"Phys Chem Chem Phys"},{"key":"10.1016\/j.nano.2026.103006_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118841","article-title":"Stimuli-responsive charge-reversal nano drug delivery system: the promising targeted carriers for tumor therapy","volume":"575","author":"Fang","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2026.103006_bb0415","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.actbio.2022.09.027","article-title":"Tumor pH-functionalized and charge-tunable nanoparticles for the nucleus\/cytoplasm-directed delivery of oxaliplatin and miRNA in the treatment of head and neck cancer","volume":"153","author":"Lo","year":"2022","journal-title":"Acta Biomater"},{"issue":"7","key":"10.1016\/j.nano.2026.103006_bb0420","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/23\/7\/075103","article-title":"Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy","volume":"23","author":"Paraskar","year":"2012","journal-title":"Nanotechnology"},{"issue":"5","key":"10.1016\/j.nano.2026.103006_bb0425","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1039\/D0RA09164B","article-title":"pH and redox dual-sensitive drug delivery system constructed based on fluorescent carbon dots","volume":"11","author":"Zhang","year":"2021","journal-title":"RSC Adv"},{"issue":"24","key":"10.1016\/j.nano.2026.103006_bb0430","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1002\/anie.201903112","article-title":"Dual-targeting dual-action platinum(IV) platform for enhanced anticancer activity and reduced nephrotoxicity","volume":"58","author":"Babak","year":"2019","journal-title":"Angew Chem Int Ed Eng"},{"issue":"31","key":"10.1016\/j.nano.2026.103006_bb0435","doi-asserted-by":"crossref","first-page":"40753","DOI":"10.1021\/acsami.4c08899","article-title":"NIR light and GSH dual-responsive upconversion nanoparticles loaded with multifunctional platinum(IV) prodrug and RGD peptide for precise cancer therapy","volume":"16","author":"Liu","year":"2024","journal-title":"ACS Appl Mater Interfaces"},{"issue":"2","key":"10.1016\/j.nano.2026.103006_bb0440","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/cas.13886","article-title":"Increased nicotinamide adenine dinucleotide pool promotes colon cancer progression by suppressing reactive oxygen species level","volume":"110","author":"Hong","year":"2019","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.nano.2026.103006_bb0445","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1158\/1078-0432.CCR-17-2575","article-title":"NAMPT is a potent oncogene in colon cancer progression that modulates cancer stem cell properties and resistance to therapy through Sirt1 and PARP","volume":"24","author":"Lucena-Cacace","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nano.2026.103006_bb0450","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12951-025-03417-8","article-title":"Oxygen vacancy-engineered bimetallic nanozymes for disrupting electron transport chain and synergistic multi-enzyme activity to reverse oxaliplatin resistance in colorectal cancer","volume":"23","author":"Zhong","year":"2025","journal-title":"J Nanobiotechnol"},{"issue":"4","key":"10.1016\/j.nano.2026.103006_bb0455","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13040570","article-title":"Mesoporous silica nanoparticles: properties and strategies for enhancing clinical effect","volume":"13","author":"Frickenstein","year":"2021","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.nano.2026.103006_bb0460","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201906846","article-title":"Metal-organic frameworks for biomedical applications","volume":"16","author":"Yang","year":"2020","journal-title":"Small"},{"issue":"12","key":"10.1016\/j.nano.2026.103006_bb0465","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/tcr.202000087","article-title":"Functionalized gold nanoparticles: synthesis, properties and biomedical applications","volume":"20","author":"Fan","year":"2020","journal-title":"Chem Rec"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb0470","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12645-017-0026-0","article-title":"Biological mechanisms of gold nanoparticle radiosensitization","volume":"8","author":"Rosa","year":"2017","journal-title":"Cancer Nanotechnol"},{"issue":"10","key":"10.1016\/j.nano.2026.103006_bb0475","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.2217\/nnm.12.165","article-title":"Gold nanoparticle imaging and radiotherapy of brain tumors in mice","volume":"8","author":"Hainfeld","year":"2013","journal-title":"Nanomedicine (London)"},{"issue":"2","key":"10.1016\/j.nano.2026.103006_bb0480","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/aa99ce","article-title":"Nanoparticle radio-enhancement: principles, progress and application to cancer treatment","volume":"63","author":"Kuncic","year":"2018","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.nano.2026.103006_bb0485","doi-asserted-by":"crossref","first-page":"13803","DOI":"10.1038\/s41598-018-31940-2","article-title":"Small, long blood half-life iodine nanoparticle for vascular and tumor imaging","volume":"8","author":"Hainfeld","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.nano.2026.103006_bb0490","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.apsb.2024.12.015","article-title":"Drug delivery systems based on mesoporous silica nanoparticles for the management of hepatic diseases","volume":"15","author":"Liu","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.nano.2026.103006_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2023.105092","article-title":"Enhancing drug loading and release with hydroxyapatite nanoparticles for efficient drug delivery: a review synthesis methods, surface ion effects, and clinical prospects","volume":"90","author":"Safitri","year":"2023","journal-title":"J Drug Delivery Sci Technol"},{"issue":"8","key":"10.1016\/j.nano.2026.103006_bb0500","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1016\/j.apsb.2021.03.019","article-title":"Metal-organic frameworks for advanced drug delivery","volume":"11","author":"He","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.nano.2026.103006_bb0505","article-title":"Fe-MOF nanoplatform: specifically overcoming oxaliplatin resistance in colorectal cancer through multifaceted pathways","volume":"26","author":"Wan","year":"2024","journal-title":"Mater Today Nano"},{"key":"10.1016\/j.nano.2026.103006_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118812","article-title":"Self-propelled biohybrids co-deliver oxaliplatin and glucose oxidase for multimodal treatment of colon cancer","volume":"193","author":"Deng","year":"2025","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.nano.2026.103006_bb0515","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat Rev Mater"},{"issue":"8","key":"10.1016\/j.nano.2026.103006_bb0520","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrc1893","article-title":"Drug penetration in solid tumours","volume":"6","author":"Minchinton","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nano.2026.103006_bb0525","article-title":"Synergistic effect of sodium butyrate and oxaliplatin on colorectal cancer","volume":"27","author":"Shuwen","year":"2022","journal-title":"Transl Oncol"},{"issue":"4","key":"10.1016\/j.nano.2026.103006_bb0530","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12212","article-title":"Essential role of membrane vesicles for biological activity of the bacteriocin micrococcin P1","volume":"11","author":"Liu","year":"2022","journal-title":"J Extracell Vesicles"},{"issue":"3","key":"10.1016\/j.nano.2026.103006_bb0535","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb0540","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1186\/s12967-025-06921-5","article-title":"Dissolving microneedles enabled delivery of oxaliplatin-sodium butyrate loaded outer membrane vesicles against rectal cancer","volume":"23","author":"Jian","year":"2025","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.nano.2026.103006_bb0545","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.1021\/acsnano.0c01676","article-title":"Nano codelivery of oxaliplatin and folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal cancer and liver metastasis","volume":"14","author":"Guo","year":"2020","journal-title":"ACS Nano"},{"issue":"7","key":"10.1016\/j.nano.2026.103006_bb0550","article-title":"DIRAS1 drives oxaliplatin resistance in colorectal cancer via PHB1-mediated mitochondrial homeostasis","volume":"14","author":"Long","year":"2025","journal-title":"Biology (Basel)"},{"issue":"8","key":"10.1016\/j.nano.2026.103006_bb0555","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41419-019-1824-6","article-title":"The synergistic effects of oxaliplatin and piperlongumine on colorectal cancer are mediated by oxidative stress","volume":"10","author":"Chen","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.nano.2026.103006_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101838","article-title":"Nanostructures for site-specific delivery of oxaliplatin cancer therapy: versatile nanoplatforms in synergistic cancer therapy","volume":"39","author":"Bagheri","year":"2024","journal-title":"Transl Oncol"},{"issue":"25","key":"10.1016\/j.nano.2026.103006_bb0565","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.3748\/wjg.v28.i25.2867","article-title":"Micelles as potential drug delivery systems for colorectal cancer treatment","volume":"28","author":"Fatfat","year":"2022","journal-title":"World J Gastroenterol"},{"issue":"11","key":"10.1016\/j.nano.2026.103006_bb0570","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1007\/s13346-024-01540-x","article-title":"Oxaliplatin lipidated prodrug synergistically enhances the anti-colorectal cancer effect of IL12 mRNA","volume":"14","author":"Liu","year":"2024","journal-title":"Drug Deliv Transl Res"},{"issue":"5","key":"10.1016\/j.nano.2026.103006_bb0575","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.ymthe.2025.03.042","article-title":"Immuno-oncology recapitulates ontogeny: modern cell and gene therapy for cancer","volume":"33","author":"Carleton","year":"2025","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb0580","doi-asserted-by":"crossref","first-page":"10987","DOI":"10.1038\/s41467-025-67328-w","article-title":"Personalized CRISPR knock-in cytokine gene therapy to remodel the tumor microenvironment and enhance CAR T cell therapy in solid tumors","volume":"16","author":"Launspach","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.nano.2026.103006_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121827","article-title":"Precision medicine-guided co-delivery of ASPN siRNA and oxaliplatin by nanoparticles to overcome chemoresistance of colorectal cancer","volume":"290","author":"Huang","year":"2022","journal-title":"Biomaterials"},{"issue":"24","key":"10.1016\/j.nano.2026.103006_bb0590","doi-asserted-by":"crossref","first-page":"12472","DOI":"10.18632\/oncotarget.2998","article-title":"Classification of current anticancer immunotherapies","volume":"5","author":"Galluzzi","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.nano.2026.103006_bb0595","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejps.2019.04.011","article-title":"Autophagy as a molecular target for cancer treatment","volume":"134","author":"Kocaturk","year":"2019","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"10.1016\/j.nano.2026.103006_bb0600","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1021\/acs.molpharmaceut.0c00961","article-title":"Tumor-associated macrophages promote oxaliplatin resistance via METTL3-mediated m6A of TRAF5 and necroptosis in colorectal cancer","volume":"18","author":"Lan","year":"2021","journal-title":"Mol Pharm"},{"issue":"11","key":"10.1016\/j.nano.2026.103006_bb0605","doi-asserted-by":"crossref","first-page":"8318","DOI":"10.1021\/acs.nanolett.9b03968","article-title":"Aggregable nanoparticles-enabled chemotherapy and autophagy inhibition combined with anti-PD-L1 antibody for improved glioma treatment","volume":"19","author":"Ruan","year":"2019","journal-title":"Nano Lett"},{"issue":"5","key":"10.1016\/j.nano.2026.103006_bb0610","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb0615","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2019.05.003","article-title":"Lactate is a natural suppressor of RLR signaling by targeting MAVS","volume":"178","author":"Zhang","year":"2019","journal-title":"Cell"},{"issue":"28","key":"10.1016\/j.nano.2026.103006_bb0620","doi-asserted-by":"crossref","first-page":"31625","DOI":"10.1021\/acsami.2c05841","article-title":"Nanodrugs incorporating LDHA siRNA inhibit M2-like polarization of TAMs and amplify autophagy to assist oxaliplatin chemotherapy against colorectal cancer","volume":"14","author":"Hu","year":"2022","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.nano.2026.103006_bb0625","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2147\/IJN.S446537","article-title":"TiO2-Ti3C2 nanocomposites utilize their photothermal activity for targeted treatment of colorectal cancer","volume":"19","author":"Wang","year":"2024","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2026.103006_bb0630","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/s41467-022-29284-7","article-title":"A hydrogen sulphide-responsive and depleting nanoplatform for cancer photodynamic therapy","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.nano.2026.103006_bb0635","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.2147\/IJN.S514659","article-title":"Advancements in nano-delivery systems for photodynamic and photothermal therapy to induce immunogenic cell death in tumor immunotherapy","volume":"20","author":"Zhao","year":"2025","journal-title":"Int J Nanomedicine"},{"issue":"18","key":"10.1016\/j.nano.2026.103006_bb0640","doi-asserted-by":"crossref","first-page":"16391","DOI":"10.1021\/acsami.9b04557","article-title":"Self-assembled oxaliplatin(IV) prodrug-porphyrin conjugate for combinational photodynamic therapy and chemotherapy","volume":"11","author":"Lim","year":"2019","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.nano.2026.103006_bb0645","article-title":"Low-temperature photothermal therapy: strategies and applications","volume":"2021","author":"Yi","year":"2021","journal-title":"Research (Wash DC)"},{"issue":"9","key":"10.1016\/j.nano.2026.103006_bb0650","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1021\/acsbiomaterials.9b00711","article-title":"Exploration of FeIII-phenol complexes for photothermal therapy and photoacoustic imaging","volume":"5","author":"Wang","year":"2019","journal-title":"ACS Biomater Sci Eng"},{"key":"10.1016\/j.nano.2026.103006_bb0655","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.actbio.2022.03.023","article-title":"Metal-organic framework-mediated multifunctional nanoparticles for combined chemo-photothermal therapy and enhanced immunotherapy against colorectal cancer","volume":"144","author":"Liu","year":"2022","journal-title":"Acta Biomater"},{"issue":"27","key":"10.1016\/j.nano.2026.103006_bb0660","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.3748\/wjg.v25.i27.3484","article-title":"Colorectal peritoneal metastases: optimal management review","volume":"25","author":"S\u00e1nchez-Hidalgo","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.nano.2026.103006_bb0665","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znaf076","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with colon cancer at high risk of peritoneal metastases: individual patient data meta-analysis","volume":"112","author":"Hamm","year":"2025","journal-title":"Br J Surg"},{"issue":"12","key":"10.1016\/j.nano.2026.103006_bb0670","doi-asserted-by":"crossref","first-page":"7528","DOI":"10.1245\/s10434-022-12312-7","article-title":"Impact of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer with peritoneal carcinomatosis: a systematic review and meta-analysis","volume":"29","author":"Martins","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"20","key":"10.1016\/j.nano.2026.103006_bb0675","article-title":"A versatile theranostic platform for colorectal cancer peritoneal metastases: real-time tumor-tracking and photothermal-enhanced chemotherapy","volume":"8","author":"Sun","year":"2021","journal-title":"Adv Sci (Weinh)"},{"issue":"4","key":"10.1016\/j.nano.2026.103006_bb0680","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e41354","article-title":"Immunotherapy in colorectal cancer: statuses and strategies","volume":"11","author":"Li","year":"2025","journal-title":"Heliyon"},{"issue":"10","key":"10.1016\/j.nano.2026.103006_bb0690","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19102890","article-title":"Cancer vaccine immunotherapy with RNA-loaded liposomes","volume":"19","author":"Sayour","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"20","key":"10.1016\/j.nano.2026.103006_bb0695","doi-asserted-by":"crossref","first-page":"11267","DOI":"10.1002\/anie.202102170","article-title":"Bispecific aptamer chimeras enable targeted protein degradation on cell membranes","volume":"60","author":"Miao","year":"2021","journal-title":"Angew Chem Int Ed Eng"},{"issue":"5","key":"10.1016\/j.nano.2026.103006_bb0700","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.4049\/jimmunol.166.5.2953","article-title":"Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA","volume":"166","author":"Heiser","year":"2001","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.nano.2026.103006_bb0705","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1349-7006.2007.00698.x","article-title":"Tumor vaccine therapy against recrudescent tumor using dendritic cells simultaneously transfected with tumor RNA and granulocyte macrophage colony-stimulating factor RNA","volume":"99","author":"Naka","year":"2008","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb0710","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1134\/S0026893317010137","article-title":"Systemic delivery of complexes of melanoma RNA with mannosylated liposomes activates highly efficient murine melanoma-specific cytotoxic T cells in vivo","volume":"51","author":"Markov","year":"2017","journal-title":"Mol Biol"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb0715","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1080\/10717544.2021.1954727","article-title":"Tumor RNA-loaded nanoliposomes increases the anti-tumor immune response in colorectal cancer","volume":"28","author":"Dai","year":"2021","journal-title":"Drug Deliv"},{"key":"10.1016\/j.nano.2026.103006_bb0720","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ijpharm.2019.06.030","article-title":"Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy","volume":"566","author":"Wan","year":"2019","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb0725","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41467-019-09221-x","article-title":"Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors","volume":"10","author":"Duan","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.nano.2026.103006_bb0730","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.addr.2020.05.005","article-title":"Membrane-core nanoparticles for cancer nanomedicine","volume":"156","author":"Guo","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"issue":"24","key":"10.1016\/j.nano.2026.103006_bb0735","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1200\/JCO.21.02500","article-title":"Esophagogastric cancers: integrating immunotherapy therapy into current practice","volume":"40","author":"Patel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nano.2026.103006_bb0740","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jconrel.2024.02.025","article-title":"Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment","volume":"368","author":"Cao","year":"2024","journal-title":"J Control Release"},{"issue":"18","key":"10.1016\/j.nano.2026.103006_bb0745","doi-asserted-by":"crossref","DOI":"10.3390\/cells11182876","article-title":"Augmented antitumor effect of unripe Rubus coreanus Miquel combined with oxaliplatin in a humanized PD-1\/PD-L1 knock-in colorectal cancer mouse model","volume":"11","author":"Lee","year":"2022","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.nano.2026.103006_bb0750","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41565-022-01134-z","article-title":"Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles","volume":"17","author":"Li","year":"2022","journal-title":"Nat Nanotechnol"},{"issue":"27","key":"10.1016\/j.nano.2026.103006_bb0755","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202007576","article-title":"Harnessing innate immunity using biomaterials for cancer immunotherapy","volume":"33","author":"Lee","year":"2021","journal-title":"Adv Mater"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb0760","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12943-020-01250-1","article-title":"Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy","volume":"19","author":"Zheng","year":"2020","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/j.nano.2026.103006_bb0765","article-title":"cGAS-STING, an important signaling pathway in diseases and their therapy","volume":"5","author":"Li","year":"2024","journal-title":"MedComm (2020)"},{"issue":"2","key":"10.1016\/j.nano.2026.103006_bb0770","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001714","article-title":"Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer","volume":"8","author":"Arai","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.nano.2026.103006_bb0775","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jconrel.2023.04.011","article-title":"Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation","volume":"357","author":"Gu","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2026.103006_bb0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2024.113906","article-title":"Dendritic polymer prodrug-based unimolecular micelles for pH-responsive co-delivery of doxorubicin and camptothecin with synergistic controlled drug release effect","volume":"238","author":"Chen","year":"2024","journal-title":"Colloids Surf B: Biointerfaces"},{"issue":"7","key":"10.1016\/j.nano.2026.103006_bb0785","first-page":"516","article-title":"Phase II trial of oxaliplatin\/irinotecan\/5-fluorouracil\/leucovorin for metastatic colorectal cancer","volume":"6","author":"McWilliams","year":"2007","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"10.1016\/j.nano.2026.103006_bb0790","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000222333","article-title":"Is higher efficacy always at the price of more side effects during chemotherapy?","volume":"4","author":"Mlineritsch","year":"2009","journal-title":"Breast Care (Basel)"},{"issue":"11","key":"10.1016\/j.nano.2026.103006_bb0795","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1007\/s11136-024-03746-5","article-title":"Overall side effect assessment of oxaliplatin toxicity in rectal cancer patients in NRG oncology\/NSABP R04","volume":"33","author":"Peipert","year":"2024","journal-title":"Qual Life Res"},{"key":"10.1016\/j.nano.2026.103006_bb0800","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2025.1582659","article-title":"Targeted and intelligent nano-drug delivery systems for colorectal cancer treatment","volume":"13","author":"Chai","year":"2025","journal-title":"Front Bioeng Biotechnol"},{"issue":"8","key":"10.1016\/j.nano.2026.103006_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2023.130385","article-title":"Gene network analysis of oxaliplatin-resistant colorectal cancer to target a crucial gene using chitosan\/hyaluronic acid\/protamine polyplexes containing CRISPR-Cas9","volume":"1867","author":"Shirani-Bidabadi","year":"2023","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.nano.2026.103006_bb0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117192","article-title":"Targeted co-delivery of rapamycin and oxaliplatin by liposomes suppresses tumor growth and metastasis of colorectal cancer","volume":"178","author":"Yu","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.nano.2026.103006_bb0815","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.00193","article-title":"Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance","volume":"7","author":"Yao","year":"2020","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.nano.2026.103006_bb0820","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12885-021-07823-7","article-title":"Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis","volume":"21","author":"Kawai","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.nano.2026.103006_bb0825","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2016.07.022","article-title":"Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy","volume":"238","author":"Zhang","year":"2016","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.nano.2026.103006_bb0830","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030889","article-title":"Codelivery of phytochemicals with conventional anticancer drugs in form of nanocarriers","volume":"15","author":"Kumar","year":"2023","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.nano.2026.103006_bb0835","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.biotechadv.2011.07.012","article-title":"Perspective on the use of humic acids from biomass as natural surfactants for industrial applications","volume":"29","author":"Salati","year":"2011","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.nano.2026.103006_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113128","article-title":"The anticancer effects of cyanidin 3-O-glucoside combined with 5-fluorouracil on lung large-cell carcinoma in nude mice","volume":"151","author":"Wu","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.nano.2026.103006_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.fhfh.2025.100224","article-title":"Synergistic anticancer enhancement: sericin nanogels co-delivery of anthocyanin and cancer drugs irinotecan, paclitaxel, and oxaliplatin","volume":"7","author":"Zhang","year":"2025","journal-title":"Food Hydrocoll Health"},{"key":"10.1016\/j.nano.2026.103006_bb0850","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/581363","article-title":"Lipoplatin formulation review article","volume":"2012","author":"Stathopoulos","year":"2012","journal-title":"J Drug Deliv"},{"issue":"5","key":"10.1016\/j.nano.2026.103006_bb0855","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/wnan.1390","article-title":"Nanoparticle formulations of cisplatin for cancer therapy","volume":"8","author":"Duan","year":"2016","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"8","key":"10.1016\/j.nano.2026.103006_bb0860","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1517\/13543780903114168","article-title":"Clinical overview on lipoplatin: a successful liposomal formulation of cisplatin","volume":"18","author":"Boulikas","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"issue":"11","key":"10.1016\/j.nano.2026.103006_bb0865","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1093\/annonc\/mdq234","article-title":"Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial","volume":"21","author":"Stathopoulos","year":"2010","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.nano.2026.103006_bb0870","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/bjc.2011.6","article-title":"A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours","volume":"104","author":"Plummer","year":"2011","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb0875","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-17-1114","article-title":"Phase Ib\/II trial of NC-6004 (nanoparticle cisplatin) plus gemcitabine in patients with advanced solid tumors","volume":"24","author":"Subbiah","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"46","key":"10.1016\/j.nano.2026.103006_bb0880","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013169","article-title":"Meta-analysis of clinical trials comparing the efficacy and safety of liposomal cisplatin versus conventional nonliposomal cisplatin in nonsmall cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)","volume":"97","author":"Xu","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.nano.2026.103006_bb0885","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1023\/A:1011199028318","article-title":"Phase I\u2013II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer","volume":"12","author":"Harrington","year":"2001","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.nano.2026.103006_bb0890","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s13346-020-00740-5","article-title":"Challenges in nanomedicine clinical translation","volume":"10","author":"Metselaar","year":"2020","journal-title":"Drug Deliv Transl Res"},{"issue":"8","key":"10.1016\/j.nano.2026.103006_bb0895","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1054\/bjoc.2001.1723","article-title":"A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin","volume":"84","author":"Veal","year":"2001","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.nano.2026.103006_bb0900","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.1021\/nn404501g","article-title":"Facing the truth about nanotechnology in drug delivery","volume":"7","author":"Park","year":"2013","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb0905","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002800050855","article-title":"Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice","volume":"43","author":"Newman","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nano.2026.103006_bb0910","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jconrel.2014.03.057","article-title":"EPR: evidence and fallacy","volume":"190","author":"Nichols","year":"2014","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.nano.2026.103006_bb0915","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2011.06.001","article-title":"Targeted drug delivery to tumors: myths, reality and possibility","volume":"153","author":"Bae","year":"2011","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2026.103006_bb0920","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jconrel.2016.10.009","article-title":"Macroporous acrylamide phantoms improve prediction of in vivo performance of in situ forming implants","volume":"243","author":"Hernandez","year":"2016","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.nano.2026.103006_bb0925","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1021\/acsnano.9b08142","article-title":"Meta-analysis of nanoparticle delivery to tumors using a physiologically based pharmacokinetic modeling and simulation approach","volume":"14","author":"Cheng","year":"2020","journal-title":"ACS Nano"},{"issue":"5","key":"10.1016\/j.nano.2026.103006_bb0930","article-title":"Quantification of cisplatin encapsulated in nanomedicine: an overview","volume":"15","author":"Zhang","year":"2025","journal-title":"Biosensors (Basel)"},{"key":"10.1016\/j.nano.2026.103006_bb0935","article-title":"Neutrophils-mediated accelerated blood clearance phenomenon in beagles and rats based on the cross-injection of non-PEGylated and PEGylated nanoemulsions","volume":"9","author":"Liu","year":"2025","journal-title":"Int J Pharm X"},{"issue":"19","key":"10.1016\/j.nano.2026.103006_bb0940","doi-asserted-by":"crossref","first-page":"10407","DOI":"10.1021\/acs.chemrev.5b00534","article-title":"Introduction: nanoparticles in medicine","volume":"115","author":"Lin","year":"2015","journal-title":"Chem Rev"},{"issue":"11","key":"10.1016\/j.nano.2026.103006_bb0945","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrd4333","article-title":"Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery","volume":"13","author":"Torchilin","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"44","key":"10.1016\/j.nano.2026.103006_bb0950","doi-asserted-by":"crossref","first-page":"17560","DOI":"10.1021\/ja207150n","article-title":"Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery","volume":"133","author":"Du","year":"2011","journal-title":"J Am Chem Soc"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb0955","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","article-title":"Biodegradable polymeric nanoparticles based drug delivery systems","volume":"75","author":"Kumari","year":"2010","journal-title":"Colloids Surf B: Biointerfaces"},{"issue":"23","key":"10.1016\/j.nano.2026.103006_bb0960","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201706759","article-title":"Cell membrane coating nanotechnology","volume":"30","author":"Fang","year":"2018","journal-title":"Adv Mater"},{"issue":"Pt A","key":"10.1016\/j.nano.2026.103006_bb0965","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10.1016\/j.nano.2026.103006_bb0970","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","article-title":"The entry of nanoparticles into solid tumours","volume":"19","author":"Sindhwani","year":"2020","journal-title":"Nat Mater"},{"key":"10.1016\/j.nano.2026.103006_bb0975","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11838","article-title":"Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy","volume":"7","author":"P\u00e9rez-Medina","year":"2016","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.nano.2026.103006_bb0980","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","article-title":"Enhancing cancer immunotherapy with nanomedicine","volume":"20","author":"Irvine","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb0985","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.drudis.2020.10.010","article-title":"Artificial intelligence in drug discovery and development","volume":"26","author":"Paul","year":"2021","journal-title":"Drug Discov Today"},{"issue":"30","key":"10.1016\/j.nano.2026.103006_bb0990","doi-asserted-by":"crossref","DOI":"10.4028\/b-XDTcg5","article-title":"Machine learning-enhanced nanoparticle design for precision cancer drug delivery","volume":"12","author":"Wang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"issue":"7","key":"10.1016\/j.nano.2026.103006_bb0995","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.nano.2017.05.014","article-title":"Quality-by-design of nanopharmaceuticals \u2014 a state of the art","volume":"13","author":"Bastogne","year":"2017","journal-title":"Nanomedicine"},{"issue":"3","key":"10.1016\/j.nano.2026.103006_bb1000","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s13346-020-00744-1","article-title":"Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation","volume":"10","author":"Taha","year":"2020","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.nano.2026.103006_bb1005","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1231401","article-title":"Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: mechanisms, pharmacokinetics and strategies","volume":"14","author":"Cheng","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb1010","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s13046-021-02141-z","article-title":"Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development","volume":"40","author":"Yang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.nano.2026.103006_bb1015","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"90","key":"10.1016\/j.nano.2026.103006_bb1020","doi-asserted-by":"crossref","first-page":"12762","DOI":"10.1039\/C8CC07858K","article-title":"An oxaliplatin(IV) prodrug-based supramolecular self-delivery nanocarrier for targeted colorectal cancer treatment","volume":"54","author":"Lim","year":"2018","journal-title":"Chem Commun"},{"issue":"1","key":"10.1016\/j.nano.2026.103006_bb1025","article-title":"Tumor-microenvironment-responsive nanomedicine for enhanced cancer immunotherapy","volume":"9","author":"Peng","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.nano.2026.103006_bb1030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-med-040210-162544","article-title":"Nanoparticle delivery of cancer drugs","volume":"63","author":"Wang","year":"2012","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.nano.2026.103006_bb1035","article-title":"Genetically programmed engineered nanodevices trigger cascade reinforcement between AMPK and cGAS-STING activation for colon cancer sonoimmunotherapy","volume":"336","author":"Zhang","year":"2026","journal-title":"Biomaterials"},{"key":"10.1016\/j.nano.2026.103006_bb1040","doi-asserted-by":"crossref","first-page":"e71434","DOI":"10.1002\/adhm.71434","article-title":"Carrier-free nanoparticles enhance photothermal-immune therapy via metabolic reprogramming in triple-negative breast cancer","author":"Hou","year":"2026","journal-title":"Adv Healthc Mater"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963426001073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963426001073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:11:36Z","timestamp":1788606696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963426001073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":208,"alternative-id":["S1549963426001073"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2026.103006","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering design of oxaliplatin nanodelivery systems: Overcoming biological barriers toward precision therapy of colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2026.103006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103006"}}